ADA 2018 Standards Address Diabetes Drugs With Proven CV Benefit


eMediNexus    09 December 2017

The American Diabetes Associations annual guidelines for 2018 include novel recommendations for use of glucose-lowering drugs with proven cardiovascular benefit in type 2 diabetes, optimization of diabetes care in elderly patients, and glucose screening of high-risk adolescents. The most impactful new recommendation necessitates the use of a glucose-lowering agent with proven cardiovascular benefit, such as the glucagonlike peptide 1 (GLP-1) agonist liraglutide, and/or mortality reduction, such as that observed with the sodium glucose cotransporter-2 (SGLT2) inhibitor empagliflozin, in type 2 diabetes patients with established atherosclerotic cardiovascular disease (ASCVD) who fail to achieve glycemic targets with lifestyle modification and metformin. The ADA 2018 Standards of Medical Care in Diabetes are published online December 8, 2017 in Diabetes Care.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.